559 related articles for article (PubMed ID: 23262059)
1. A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics.
Steichen SD; Caldorera-Moore M; Peppas NA
Eur J Pharm Sci; 2013 Feb; 48(3):416-27. PubMed ID: 23262059
[TBL] [Abstract][Full Text] [Related]
2. Classification of stimuli-responsive polymers as anticancer drug delivery systems.
Taghizadeh B; Taranejoo S; Monemian SA; Salehi Moghaddam Z; Daliri K; Derakhshankhah H; Derakhshani Z
Drug Deliv; 2015 Feb; 22(2):145-55. PubMed ID: 24547737
[TBL] [Abstract][Full Text] [Related]
3. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
4. Production and characterization of gamma-polyglutamic acid nanoparticles for controlled anticancer drug release.
Manocha B; Margaritis A
Crit Rev Biotechnol; 2008; 28(2):83-99. PubMed ID: 18568849
[TBL] [Abstract][Full Text] [Related]
5. Targeted, triggered drug delivery to tumor and biofilm microenvironments.
Benoit DS; Koo H
Nanomedicine (Lond); 2016 Apr; 11(8):873-9. PubMed ID: 26987892
[No Abstract] [Full Text] [Related]
6. Design considerations for nanotherapeutics in oncology.
Stylianopoulos T; Jain RK
Nanomedicine; 2015 Nov; 11(8):1893-907. PubMed ID: 26282377
[TBL] [Abstract][Full Text] [Related]
7. Tumor targeting strategies for chitosan-based nanoparticles.
Zhang X; Yang X; Ji J; Liu A; Zhai G
Colloids Surf B Biointerfaces; 2016 Dec; 148():460-473. PubMed ID: 27665379
[TBL] [Abstract][Full Text] [Related]
8. Peptide targeted lipid nanoparticles for anticancer drug delivery.
Pearce TR; Shroff K; Kokkoli E
Adv Mater; 2012 Jul; 24(28):3803-22, 3710. PubMed ID: 22674563
[TBL] [Abstract][Full Text] [Related]
9. Programmed pH/reduction-responsive nanoparticles for efficient delivery of antitumor agents in vivo.
Chen WL; Yang SD; Li F; Qu CX; Liu Y; Wang Y; Wang DD; Zhang XN
Acta Biomater; 2018 Nov; 81():219-230. PubMed ID: 30267887
[TBL] [Abstract][Full Text] [Related]
10. Tumor-Associated Fibroblast-Targeting Nanoparticles for Enhancing Solid Tumor Therapy: Progress and Challenges.
Li W; Little N; Park J; Foster CA; Chen J; Lu J
Mol Pharm; 2021 Aug; 18(8):2889-2905. PubMed ID: 34260250
[TBL] [Abstract][Full Text] [Related]
11. Advanced engineered nanoparticulate platforms to address key biological barriers for delivering chemotherapeutic agents to target sites.
Cao J; Huang D; Peppas NA
Adv Drug Deliv Rev; 2020 Dec; 167():170-188. PubMed ID: 32622022
[TBL] [Abstract][Full Text] [Related]
12. Nanoparticle targeting of anti-cancer drugs that alter intracellular signaling or influence the tumor microenvironment.
Kanapathipillai M; Brock A; Ingber DE
Adv Drug Deliv Rev; 2014 Dec; 79-80():107-18. PubMed ID: 24819216
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in active targeting of nanomaterials for anticancer drug delivery.
Dutta B; Barick KC; Hassan PA
Adv Colloid Interface Sci; 2021 Oct; 296():102509. PubMed ID: 34455211
[TBL] [Abstract][Full Text] [Related]
14. Tumor vascular-targeted co-delivery of anti-angiogenesis and chemotherapeutic agents by mesoporous silica nanoparticle-based drug delivery system for synergetic therapy of tumor.
Li X; Wu M; Pan L; Shi J
Int J Nanomedicine; 2016; 11():93-105. PubMed ID: 26766908
[TBL] [Abstract][Full Text] [Related]
15. Factors Influencing the Delivery Efficiency of Cancer Nanomedicines.
Ullah R; Wazir J; Khan FU; Diallo MT; Ihsan AU; Mikrani R; Aquib M; Zhou X
AAPS PharmSciTech; 2020 May; 21(4):132. PubMed ID: 32409932
[TBL] [Abstract][Full Text] [Related]
16. From The Mine to Cancer Therapy: Natural and Biodegradable Theranostic Silicon Nanocarriers from Diatoms for Sustained Delivery of Chemotherapeutics.
Maher S; Kumeria T; Wang Y; Kaur G; Fathalla D; Fetih G; Santos A; Habib F; Evdokiou A; Losic D
Adv Healthc Mater; 2016 Oct; 5(20):2667-2678. PubMed ID: 27594524
[TBL] [Abstract][Full Text] [Related]
17. Polymeric nanoparticles for cancer therapy.
Parveen S; Sahoo SK
J Drug Target; 2008 Feb; 16(2):108-23. PubMed ID: 18274932
[TBL] [Abstract][Full Text] [Related]
18. Targeting tumor microenvironment with PEG-based amphiphilic nanoparticles to overcome chemoresistance.
Chen S; Yang K; Tuguntaev RG; Mozhi A; Zhang J; Wang PC; Liang XJ
Nanomedicine; 2016 Feb; 12(2):269-86. PubMed ID: 26707818
[TBL] [Abstract][Full Text] [Related]
19. Nanomedicines for cancer therapy: current status, challenges and future prospects.
Bor G; Mat Azmi ID; Yaghmur A
Ther Deliv; 2019 Feb; 10(2):113-132. PubMed ID: 30678550
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in drug delivery systems for enhancing drug penetration into tumors.
He B; Sui X; Yu B; Wang S; Shen Y; Cong H
Drug Deliv; 2020 Dec; 27(1):1474-1490. PubMed ID: 33100061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
